Celltrion, Inc.
068270
株式のランク
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
株価
$146.63
時価総額
$33.44B
変化（1日）
-1.52%
変化（1年）
23.60%
国
KR
取引 Celltrion, Inc. (068270)
カテゴリー
Healthcare
Celltrion, Inc.（068270）の営業利益率
October 2026 時点の営業利益率 TTM: 31.56%
Celltrion, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 31.56% です。2024 年末時点では 13.83% でした。
Celltrion, Inc. の営業利益率の履歴（2007 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 31.56% | 12.43% |
| 2025 | 28.07% | 102.96% |
| 2024 | 13.83% | -53.79% |
| 2023 | 29.93% | 5.61% |
| 2022 | 28.34% | -27.89% |
| 2021 | 39.30% | 1.13% |
| 2020 | 38.86% | 14.94% |
| 2019 | 33.81% | 2.77% |
| 2018 | 32.90% | -37.50% |
| 2017 | 52.64% | 41.35% |
| 2016 | 37.24% | -13.21% |
| 2015 | 42.91% | 0.33% |
| 2014 | 42.77% | -3.10% |
| 2013 | 44.14% | -20.91% |
| 2012 | 55.81% | -13.15% |
| 2011 | 64.26% | 9.06% |
| 2010 | 58.92% | 19.51% |
| 2009 | 49.30% | 34.08% |
| 2008 | 36.77% | 1,237.09% |
| 2007 | 2.75% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 28.81% | -99.09% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。